LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Lista de Ações・Incyte Corp

Search

Incyte Corp

Fechado

SetorSaúde

105.37 2.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

102.36

Máximo

110.19

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	14.215 49.052
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 368M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+6.93% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.1B 20B
Abertura anterior	103.26
Fecho anterior	105.37

Sentimento de Notícias

By Acuity

32%

68%

81 / 344 Ranking em Healthcare

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Ganhos

Correction to Oracle Reports Higher 4Q Profit Article

10 de jun. de 2026, 23:19 UTC

Ações em Alta

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 de jun. de 2026, 23:09 UTC

Grandes Movimentos do Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 de jun. de 2026, 23:04 UTC

Ganhos

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 de jun. de 2026, 20:44 UTC

Grandes Movimentos do Mercado

Caterpillar Raises Quarterly Dividend 8%

10 de jun. de 2026, 23:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Should Take No Options Off The Table

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 de jun. de 2026, 23:47 UTC

Conversa de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 de jun. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 de jun. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 de jun. de 2026, 23:32 UTC

Conversa de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 de jun. de 2026, 23:20 UTC

Conversa de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 de jun. de 2026, 22:05 UTC

Conversa de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

10 de jun. de 2026, 21:57 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:52 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:35 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:22 UTC

Ganhos

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de jun. de 2026, 20:39 UTC

Conversa de Mercado

Ganhos

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 de jun. de 2026, 20:34 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Ganhos

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

6.93% parte superior

Previsão para 12 meses

Média 110.38 USD 6.93%

Máximo 140 USD

Mínimo 75 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

8

Comprar

10

Manter

1

Vender

Com base em 19 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

81 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Outras ações do setor

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat